Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN UPDATED on 06/16/2026 Since 2020, the FDA has significantly expanded the immuno-oncology (IO) landscape, approving several novel agents and expanding existing immunotherapies (e.g., checkpoint inhibitors, CAR-T, bispecific antibodies) for early-stage and metastatic solid and hematologic … Continue reading Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com